The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
650 jobs Number of planned job losses
Announcement Date
21 February 2013
Employment effect (start)
21 February 2013
Foreseen end date
Description
Pharmaceutical company Abbott is currently in the process of making 650 of its staff in Ireland and the US redundant. The company, which produces pharmaceuticals, medical and nutritional products, says that these job reduction measures form part of a previously communicated adjustment strategy set out to increase its efficiency.
According to reports, the company has issued redundancy notices at its Temecula plant in California, US, which specializes in vascular devices, affecting 450 of its staff. The job cuts were primarily located in the company’s manufacturing and manufacturing support divisions, affecting full-time employees only. While the Temecula plant continues to employ around 2,000 staff, the plant has witnessed a loss of 1,000 positions since January 2012.
At the same time, the company also intends to eliminate 200 positions in Ireland. The job cuts will be affected at the company’s Clonmel plant, which also specializes in vascular devices and currently employs around 1,400 staff. According to Abbott, these job reduction measures have become necessary due to a downturn in demand for the company’s older products.
According to reports, the company wants to focus on voluntary redundancies and also plans to not renew temporary contracts. Moreover, Abbott remains committed to assist those affected by redundancies and in Ireland a 30-day consultation period with employees has been initiated.
The global healthcare company currently employs around 70,000 employees across 150 countries. American based Abbott has been continuously reducing its staff over the past 3 years (see here).
Sources
21 February 2013: The Press Enterprise
21 February 2013: Belfast Telegraph
21 February 2013: FierceMedicalDevices
21 February 2013: Murrieta Patch
Citation
Eurofound (2013), Abbott, Internal restructuring in World, factsheet number 74968, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/74968.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
